A shift towards value-based healthcare (VBC) has prompted industry participants to collaborate on innovative approaches to deliver improved outcomes in a more cost-effective manner. To reset perceptions and realize opportunities in VBC, manufacturers need to be proactive, establishing programs and partnerships that demonstrate outcome benefits and clearly define and articulate the value they add to the healthcare system.
To read more, click the link below.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.